Amphastar Pharmaceuticals, Inc. (AMPH) |
| 23.74 0.78 (3.4%) 09-02 16:00 |
| Open: | 23.06 |
| High: | 23.825 |
| Low: | 23.0275 |
| Volume: | 436,695 |
| Market Cap: | 1,047(M) |
| PE Ratio: | 8.1 |
| Exchange: | NASDAQ Global Select |
| Industry: | Drug Manufacturers - Specialty & Generic |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 27.83 |
| Resistance 1: | 23.83 |
| Pivot price: | 21.80 |
| Support 1: | 21.18 |
| Support 2: | 19.55 |
| 52w High: | 31.1 |
| 52w Low: | 16.65 |
Amphastar Pharmaceuticals, Inc., established in 1996 and based in Rancho Cucamonga, California, functions as a biopharmaceutical enterprise. The company is engaged in the creation, production, commercialization, and distribution of both generic and proprietary pharmaceutical products, which include injectables, inhalants, and intranasal formulations. Its market presence extends across the United States, China, and France. Amphastar's operations are divided into two primary segments: Finished Pharmaceutical Products and Active Pharmaceutical Ingredients (API). The company's extensive product portfolio encompasses a variety of crucial medications. These feature Primatene Mist, an over-the-counter epinephrine inhaler for the temporary alleviation of mild asthma symptoms; Enoxaparin, a low molecular weight heparin utilized for the prevention and treatment of deep vein thrombosis; and Naloxone, an essential treatment for opioid overdose. Other significant offerings include emergency Glucagon injection kits; Cortrosyn, a diagnostic agent for adrenocortical insufficiency; and Amphadase, a bovine-sourced hyaluronidase injection that aids in the absorption and dispersion of other administered drugs. Amphastar additionally supplies Epinephrine injections for severe allergic reactions; various lidocaine products (such as a jelly for urological procedures and a topical solution for other applications); Phytonadione injection (Vitamin K1) for newborns; and specialized emergency syringe products for hospital use. Furthermore, the company provides Morphine injections for patient-controlled analgesia and Lorazepam injections for surgical and medical procedures. More advanced therapeutics consist of Neostigmine methylsulfate injection to manage myasthenia gravis and reverse muscle relaxant effects, and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Beyond its finished pharmaceutical goods, Amphastar also acts as a distributor for recombinant human insulin API and porcine insulin API. The company caters to a broad spectrum of healthcare providers, including hospitals, various care facilities, clinics, and physicians' offices.
| EPS | 1.690 |
| Book Value | 18.060 |
| PEG Ratio | 0.00 |
| Gross Profit | 8.183 |
| Profit Margin (%) | 10.76 |
| Operating Margin (%) | 21.60 |
| Return on Assets (ttm) | 5.1 |
| Return on Equity (ttm) | 10.3 |
Tue, 01 Sep 2026
Amphastar (NASDAQ: AMPH) VP plans Rule 144 stock sale led by 10,000-share option exercise - Stock Titan
Tue, 01 Sep 2026
Amphastar Pharmaceuticals to Present at the Wells Fargo 21st Annual Healthcare Conference - Stock Titan
Sat, 29 Aug 2026
Amphastar Pharmaceuticals, Inc. $AMPH Stock Holdings Lifted by Algert Global LLC - MarketBeat
Fri, 28 Aug 2026
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stock Price Passes Above 50-Day Moving Average - Should You Sell? - MarketBeat
Sat, 22 Aug 2026
Analysts Estimate Amphastar Pharmaceuticals (AMPH) to Report a Decline in Earnings: What to Look Out for - Eastern Progress
Thu, 06 Aug 2026
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2026 - PR Newswire
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |